{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T15:47:08Z","timestamp":1771861628032,"version":"3.50.1"},"reference-count":33,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2015,11,20]],"date-time":"2015-11-20T00:00:00Z","timestamp":1447977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2016,3,15]]},"abstract":"<jats:p>We report on a phase II clinical trial to determine the effect of a concurrent ultra\u2010fractionated radiotherapy and temozolomide treatment in inoperable glioblastoma patients. A phase II study opened; patients over 18 years of age who were able to give informed consent and had histologically proven, newly diagnosed inoperable diagnosed and supratentorial glioblastoma were eligible. Three doses of 0.75 Gy spaced apart by at least 4 hr were delivered daily, 5 days a week for six consecutive weeks for a total of 67.5 Gy. Chemotherapy was administered during the same period, which consisted of temozolomide given at a dose of 75 mg\/m<jats:sup>2<\/jats:sup> for 7 days a week. After a 4\u2010week break, chemotherapy was resumed for up to six cycles of adjuvant temozolomide treatment, given every 28 days, according to the standard 5\u2010day regimen. Tolerance and toxicity were the primary endpoints; survival and progression\u2010free survival were the secondary endpoints. In total, 40 patients were enrolled in this study, 29 men and 11 women. The median age was 58 years, and the median Karnofsky performance status was 80. The concomitant ultra\u2010fractionated radiotherapy and temozolomide treatment was well tolerated. Complete responses were seen in four patients, and partial responses were reported in seven patients. The median survival from the initial diagnosis was 16 months. Several long\u2010term survivors were noted. Concurrent ultra\u2010fractionated radiation therapy and temozolomide treatment are well accepted by the patients. The results showed encouraging survival rates for these unfavorable patients.<\/jats:p>","DOI":"10.1002\/ijc.29898","type":"journal-article","created":{"date-parts":[[2015,10,26]],"date-time":"2015-10-26T16:49:38Z","timestamp":1445878178000},"page":"1538-1544","source":"Crossref","is-referenced-by-count":7,"title":["A concurrent ultra\u2010fractionated radiation therapy and temozolomide treatment: A promising therapy for newly diagnosed, inoperable glioblastoma"],"prefix":"10.1002","volume":"138","author":[{"given":"P.","family":"Beauchesne","sequence":"first","affiliation":[{"name":"Service de Neuro\u2010Oncologie, CHU De Nancy Nancy France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Quillien","sequence":"additional","affiliation":[{"name":"Departement de Biologie Centre E Marquis Rennes France"},{"name":"CNRS, UMR 6290, Universite Rennes 1 Rennes France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Faure","sequence":"additional","affiliation":[{"name":"Centre Private de Radioth\u00e9rapie, Centre C Bernard Metz France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Bernier","sequence":"additional","affiliation":[{"name":"Departement de Radiath\u00e9rapie Institut De Canc\u00e9rologie Lorrain Vandoeuvre France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Noel","sequence":"additional","affiliation":[{"name":"Departement de Radioth\u00e9rapie Centre P Strauss Strasbourg France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Quetin","sequence":"additional","affiliation":[{"name":"Departement de Radioth\u00e9rapie CHR Metz Mercy  France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Gorlia","sequence":"additional","affiliation":[{"name":"EORTC Data Center Bruxelles Belgique"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Carnin","sequence":"additional","affiliation":[{"name":"Service de Neuro\u2010Oncologie, CHU De Nancy Nancy France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Pedeux","sequence":"additional","affiliation":[{"name":"INSERM U917 Rennes France"},{"name":"INSERM ER440\u2010OSS, Centre Eug\u00e8ne Marquis Rennes France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,11,20]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12328-8"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200101113440207"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19930415)71:8<2585::AID-CNCR2820710825>3.0.CO;2-S"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08091-1"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043330"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2388(199801\/02)14:1<34::AID-SSU5>3.0.CO;2-3"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers5041199"},{"key":"e_1_2_5_9_1","first-page":"565","article-title":"The use of \u2018top\u2010up\u2019 experiments to investigate the effect of very small doses per fraction in mouse skin","volume":"49","author":"Joiner MC","year":"1986","journal-title":"Int J Radiat Biol Relat Phys Chem Med"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(00)01471-1"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0167-8140(94)90450-2"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/095530096145832"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/09553009314450831"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.2307\/3578255"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.11.071"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/09553000110041326"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/095530099139214"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.11033"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noq008"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.7.1277"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27392"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/02841860310014679"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.5732\/cjc.013.10217"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.4103\/2152-7806.132138"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70025-7"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(89)90939-5"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1010621400203"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-8140(87)80215-3"},{"key":"e_1_2_5_29_1","first-page":"2457","article-title":"Hyperfractionated radiotherapy and multi\u2010agent chemotherapy (procarbazine, ACNU and vincristine) for high\u2010grade gliomas: a prospective study","volume":"26","author":"Ogawa K","year":"2006","journal-title":"Anticancer Res"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(00)01458-9"},{"key":"e_1_2_5_31_1","first-page":"15:1535","article-title":"Final report of a phase I\/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83\u201002","author":"Werner\u2010Wasik M","year":"1996","journal-title":"Cancer"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu148"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1308345"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1308573"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.29898","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.29898","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T12:16:38Z","timestamp":1696335398000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.29898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,20]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,3,15]]}},"alternative-id":["10.1002\/ijc.29898"],"URL":"https:\/\/doi.org\/10.1002\/ijc.29898","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,20]]}}}